Agenus is redirecting its Phase 3 colon-cancer strategy.

The biotech company said on July 13 that it will stop providing financial support for its BATTMAN study and make ROBBIN, a planned Phase 3 trial of BOT+BAL before colon-cancer surgery, its central development priority.

The shift is backed by a private placement expected to provide about $85 million upfront. Agenus could receive another $255 million if accompanying warrants are fully exercised, bringing potential gross proceeds to $340 million.

Investors rewarded the combination of a narrower clinical strategy and new capital. Agenus (AGEN) shares were recently trading at $6.46, up 93.1% from July 10’s close, according to Yahoo Finance, after reaching $8.70 earlier in the session.

The financing gives the company $85 million now and a possible route to the rest through warrants, a distinction that shapes both the opportunity and the dilution risk for shareholders.

Agenus chooses ROBBIN over BATTMAN

Agenus plans to direct the financing toward ROBBIN, a randomized global Phase 3 study of botensilimab plus balstilimab, known as BOT+BAL, in patients with high-risk Stage II and Stage III microsatellite-stable colon cancer.

The trial is expected to enroll about 850 patients. It will compare patients who receive BOT+BAL before surgery with patients who proceed directly to surgery, with event-free survival serving as the primary endpoint.

The company expects the first ROBBIN patient to be dosed in the first quarter of 2027. Interim pathologic-response data are expected in the second half of that year, followed by an interim event-free-survival analysis in 2029 and a final analysis in 2030.

Agenus is making room for that program by discontinuing financial support for BATTMAN, its Phase 3 trial in patients with late-line metastatic MSS colorectal cancer. The company said it will continue meeting its obligations to patients already receiving treatment.

Our plan to prioritize neoadjuvant BOT+BAL in MSS colon cancer reflects both the strength of the emerging clinical evidence.

The decision leaves Agenus with a more concentrated Phase 3 strategy. Rather than financing two late-stage paths at once, the company is placing more of its capital behind the earlier-treatment setting it considers its higher-value opportunity.

Related: Jensen: How to Play Agenus Using Options

Agenus gets upfront cash with more tied to warrants

The upfront portion of the transaction is expected to generate about $85 million before expenses.

That amount provides immediate relief for a company that ended the first quarter with $35 million in cash and cash equivalents. Agenus reported about $51.8 million in cash payments during the quarter, although it said some of those costs were tied to one-time obligations and manufacturing investments.

The remaining $255 million depends on investors exercising two groups of purchase warrants.

Agenus agreed to issue about 23 million common shares or pre-funded warrants as part of the initial placement. Investors will also receive Series A warrants covering about 21.1 million shares at an exercise price of $4.02 and Series B warrants covering about 33.8 million shares at $5.03.

The company priced the initial shares and both warrant tranches at a premium to Agenus’s July 10 closing price. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals.

The financing creates two different runway scenarios

• No warrant exercise: Agenus said its existing cash and the upfront placement proceeds are expected to support operations into the third quarter of 2027.
• Full warrant exercise: If the Series A and Series B warrants are fully exercised, the company expects its cash runway to extend through the end of 2031.
• Why it matters: The $85 million upfront payment helps Agenus reach the start of ROBBIN, but the longer runway depends on future warrant exercises rather than cash already committed to the company.

Why investors cheered despite the dilution 

Selling new shares and issuing warrants can reduce existing shareholders’ ownership percentage.

In this case, investors focused instead on three features of the transaction: the premium pricing, the participation of specialist biotech investors, and the removal of some near-term financing pressure.

Related: BridgeBio stock jumps after rival heart drug fails key trial

Agenus also rose against a weaker market backdrop. The Nasdaq and S&P 500 were lower during morning trading, making the move in AGEN more clearly tied to the company announcement than to a broad biotech or equity rally.

The warrants introduce a second market question. If Agenus shares remain above the $4.02 and $5.03 exercise prices, warrant holders have a stronger economic incentive to exercise them, although the additional proceeds and share issuance are not guaranteed.

The stock’s rally therefore reflects more than the $85 million arriving upfront. Investors are also placing value on the chance that Agenus can fund ROBBIN more fully without returning immediately to the market for another financing.

Monday’s move suggests investors prefer a focused Phase 3 plan with near-term financing to a broader strategy constrained by cash. The next milestones are now specific: closing the placement, beginning ROBBIN in 2027, and determining whether the warrants can provide the capital needed for the later stages of the trial.

Related: Biotech stock sends Wall Street surprising signal